20 May 2013
Keywords: GlaxoSmithKline, Votrient, Soft tissue sarcomas, EMA, Approval
Article | 09 August 2012
UK pharma giant GlaxoSmithKline (LSE: GSK) says that the European Medicines Agency has approved Votrient (pazopanib) for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 August 2012
10 August 2012
17 May 2013
© 2013 thepharmaletter.com